Repository logo
 
Publication

Análise da revisão Cochrane: o papel dos antiagregantes plaquetários para prevenir a pré-eclâmpsia e as suas complicações: Cochrane Database Syst Rev. 2019;10:CD004659

dc.contributor.authorReis-de-Carvalho, Catarina
dc.contributor.authorVieira, Miguel Bigotte
dc.contributor.authorCosta, João
dc.contributor.authorCarneiro, António Vaz
dc.date.accessioned2023-06-16T14:03:23Z
dc.date.available2023-06-16T14:03:23Z
dc.date.issued2021
dc.descriptionCopyright © Ordem dos Médicos 2021. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.pt_PT
dc.description.abstractPre-eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses that antiplatelet agents, low-dose aspirin in particular, might prevent or delay development of pre-eclampsia. This Cochrane review aimed to assess the effectiveness and safety of antiplatelet agents, such as aspirin and dipyridamole, when given to women at risk of developing preeclampsia. A systematic review of literature was carried out by searching the following databases up to September 2019: Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), and reference lists of retrieved studies. Seventy-seven trials were included, including 40 249 women at risk of developing pre-eclampsia. About 80% of these women were evaluated in nine of the 77 trials included, with eight of these nine trials providing individual data. Interventions were administration of an antiplatelet agent, and comparisons were either placebo or no antiplatelet. The present review provides high-quality evidence that administering low-dose aspirin (50 - 150 mg) to pregnant women led to small-to-moderate benefits, including reductions in the risk of pre-eclampsia, preterm birth, small-for-gestational age fetus, and fetal or neonatal death. Overall, administering antiplatelet agents to 1000 women led to 20 fewer pregnancies with serious adverse outcomes.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationActa Med Port. 2021 Dec 2;34(12):810-814pt_PT
dc.identifier.doi10.20344/amp.15995pt_PT
dc.identifier.eissn1646-0758
dc.identifier.issn0870-399X
dc.identifier.urihttp://hdl.handle.net/10451/58254
dc.language.isoporpt_PT
dc.peerreviewedyespt_PT
dc.publisherOrdem dos Médicospt_PT
dc.relation.publisherversionhttps://www.actamedicaportuguesa.com/revista/index.php/amp/indexpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectPlatelet aggregation inhibitorspt_PT
dc.subjectTherapeutic usept_PT
dc.subjectPre-eclampsiapt_PT
dc.subjectDrug therapypt_PT
dc.subjectPrevention and controlpt_PT
dc.subjectPrenatal carept_PT
dc.subjectRandomized controlled trials as topicpt_PT
dc.titleAnálise da revisão Cochrane: o papel dos antiagregantes plaquetários para prevenir a pré-eclâmpsia e as suas complicações: Cochrane Database Syst Rev. 2019;10:CD004659pt_PT
dc.title.alternativeAnalysis of the Cochrane review: antiplatelet agents for preventing pre-eclampsia and its complications: Cochrane Database Syst Rev. 2019;10:CD004659pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage814pt_PT
oaire.citation.issue12pt_PT
oaire.citation.startPage810pt_PT
oaire.citation.titleActa Médica Portuguesapt_PT
oaire.citation.volume34pt_PT
person.familyNameReis-de-Carvalho
person.familyNameBigotte Vieira
person.familyNameCosta
person.familyNameVaz Carneiro
person.givenNameCatarina
person.givenNameMiguel
person.givenNameJoão
person.givenNameAntónio
person.identifier591378
person.identifier480560
person.identifier.ciencia-idFF17-2C76-E2CC
person.identifier.orcid0000-0002-5962-1560
person.identifier.orcid0000-0003-0528-2716
person.identifier.orcid0000-0002-5831-4921
person.identifier.orcid0000-0002-2783-0544
person.identifier.ridV-4629-2018
person.identifier.ridL-8026-2013
person.identifier.scopus-author-id57192837006
person.identifier.scopus-author-id55499748300
person.identifier.scopus-author-id7006837792
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication471dcd48-a81d-48e7-9272-e2de818abdbe
relation.isAuthorOfPublication8d118e09-0abf-4347-8e5c-cc53c7cbd4bd
relation.isAuthorOfPublication0924f405-2d3a-4914-9097-24aa639bd97f
relation.isAuthorOfPublication376d157f-1127-4663-9d99-038dac28f37d
relation.isAuthorOfPublication.latestForDiscovery0924f405-2d3a-4914-9097-24aa639bd97f

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Antiagregantes_plaquetarios.pdf
Size:
417.31 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.2 KB
Format:
Item-specific license agreed upon to submission
Description: